FLT3 and acute myeloid leukemia: We treated FLT3/ITD AML cell lines Molm14 and MV4;11 with several FLT3 TKI (sorafenib, quizartinib, lestaurtinib, crenolanib, and gilteritinib) at concentrations effective for sustained FLT3 inhibition for 24 h.